Impact of chemotherapy-induced neutropenia on quality of life: A prospective pilot investigation

Supportive Care in Cancer

Volumn 13, Issue 7, 2005, Pages 522-528

  Fortner, Barry V ^a,c   Schwartzberg, Lee ^a   Tauer, Kurt ^a   Houts, Arthur C ^a   Hackett, James ^b   Stolshek, Brad S ^b  

^a WEST CLINIC   (United States)

^b AMGEN INC   (United States)

^c SOS/ACORN   (United States)

Author keywords

Chemotherapy induced neutropenia; Quality of life

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PREDNISONE; VINCRISTINE;

ADULT; ANXIETY; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CONTROLLED STUDY; DISEASE ASSOCIATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LUNG CARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NEUTROPENIA; OVARY CARCINOMA; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; QUALITY OF LIFE;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANXIETY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PREDNISONE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; VINCRISTINE;

EID: 21644479915     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0757-4     Document Type: Article

References (23)

1. Adams VR (2000) Adverse events associated with chemotherapy for common cancers. Pharmacotherapy 20(7 Pt 2):96S-103S
2. Blackwell S, Crawford J (1992) Colony-stimulating factors: clinical applications. Pharmacotherapy 12(2 Pt 2):20S-31S
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328-340
4. Meza L, Baselga J, Holmes FA, Liang B, Breddy J (2002) Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy (abstract 2840). Proc ASCO 21:255b
5. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, et al (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80(6):1430-1436
6. National Cancer Institute (2003) Common toxicity criteria (CTC version 2.0). Washington, DC
7. Alexander SW, Pizzo PA (1999) Current considerations in the management of fever and neutropenia. Curr Clin Top Infect Dis 19:160-180
8. Lehrnbecher T, Chanock SJ (1998) Controversies in the treatment of neutropenia in cancer patients. Curr Opin Hematol 5(1):26-32
9. Broeckel JA, Jacobsen PB, Balducci L, Horton J, Lyman GH (2000) Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 62(2):141-150
10. Macquart-Moulin G, Viens P, Palangie T, Bouscary ML, Delozier T, Roche H, et al (2000) High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 18(4):754-764
11. Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G (2000) Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 19(6):436-445
12. Swain SM, Rowland J, Weinfurt K, Berg C, Lippman ME, Walton L, et al (1996) Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. J Clin Oncol 14(5):1565-1572
13. Glaspy J, Hackett J, Flyer P, Dunford D, Liang B (2001) Febrile neutropenia is associated with an increase in the Incidence, duration, and severity of chemotherapy toxicities (abstract 1812). American Society of Hematology Orlando, FL, 7-11 December
14. Ware JE, Snow KK, Kosinski M, Gandek B (1993) SF-36 health survey: manual and interpretation guide. The Health Institute New England Medical Center, Boston
15. Ware JE, Kosinski MA (2001) SF-36 Physical and mental health summary scales: a manual for users of version 1, 2nd edn. QualityMetric, Lincoln, RI
16. Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC (2003) The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage 26(6): 1077-1092
17. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361-370
18. Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52(2):69-77
19. Smith AB, Selby PJ, Velikova G, Stark D, Wright EP, Gould A, et al (2002) Factor analysis of the Hospital Anxiety and Depression Scale from a large cancer population. Psychol Psychother 75(Pt 2):165-176
20. Merluzzi TV, Sanchez AM (1997) Factor structure of the Psychosocial Adjustment to Illness Scale (Self-Report) for persons with cancer. Psychol Assess 9(3):269-276
21. Crosby RD, Kolotkin RL, Williams GR (2003) Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 56(5):395-407
22. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D (1999) Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 15 (2):141-155
23. Pico JL, Avila-Garavito A, Naccache P (1998) Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3(6):446-451